Redeye comments on Lytix’ third results in 2023. In October, the first readout from the phase II tri...
Sales of SEK 62m, up 26% y-o-y, EBIT -4.9m (-25.8m) Circular Energy continues growth, production at ...
Sales of SEK 33.4m, up 50.3% y-o-y, adj. EBIT SEK -2.
Growth of 17.5% and strong adj. EBITA margin of 8.8% (4.
Q3 income 6% below our ABGSCe due to lower NCI... .
STENOCARE published on November 9th its Q3-report for 2023.
Redeye was hoping for a bit more, particularly in terms of top-line.
Redeye leaves a comment on today’s news that Einar Pontén is stepping down as the CEO of Lipum and t...
Redeye is encouraged by the news that Kontigo Care has partnered strategically with its first corpor...
Redeye updates its view of Egetis following the Q3 report and recent events in the company.
Redeye has opened an Analyst Q&A in conjunction with the latest research update on Xspray Pharma.
Rör sig mot våra helårsestimat och guidning Omsättningen i kvartalet uppgick till EUR 31,8m, vilket ...
Realistiskt att nå SPARKLE-resultat med nuvarande kassa Ascelia levererade en Q3-rapport som var enl...
Stabil finansiell position Egetis rapport för det tredje kvartalet innehöll inga överraskningar.
Marimekko reported Q3 figures that were largely in line with our estimates.
Sales and EBITA 0% and 5% vs. ABGSCe Customer intake -2,800 q-o-q (ABGSCe +500) Expect small estimat...
Redeye sees a rather soft Q3 report from Xavi, with sales and adjusted EBIT coming below our expecta...
Redeye is happy to see Railcare clearly beating our Q3 earnings forecast.
Sales +12% and adj. EBIT SEK +2m vs. ABGSCe Sales beat due to the fast-growing Nonwoven & F.
Redeye comments on QleanAir’s Q3 figures where sales were in line with estimates posting an 11% grow...
